Crinetics pharmaceuticals, inc. (CRNX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Grant revenues

897

1,193

1,653

1,696

2,353

2,428

2,175

2,267

2,442

2,045

0

0

0

Operating expenses:
Research and development

48,113

41,506

37,014

32,077

27,014

24,479

19,390

15,027

11,888

9,233

0

0

0

General and administrative

14,354

13,519

12,688

10,509

8,567

6,659

4,565

3,324

2,598

1,939

0

0

0

Total operating expenses

62,467

55,025

49,702

42,586

35,581

31,138

23,955

18,351

14,486

11,172

0

0

0

Loss from operations

-61,570

-53,832

-48,049

-40,890

-33,228

-28,710

-21,653

-15,226

0

-

0

0

-

Other income (expense):
Interest income

3,006

3,460

3,804

3,503

2,694

1,748

755

228

0

-

0

0

-

Interest expense

-

-

-

-

-

-

-

-

-

-

0

0

-

Other income (expense), net

0

-

0

0

0

-

0

0

0

-

0

0

-

Total other income (expense), net

2,804

3,410

3,681

3,364

2,561

1,595

651

164

0

-

0

0

-

Net loss

-58,766

-50,422

-44,368

-37,526

-30,667

-27,115

-21,141

-15,935

-12,015

-9,157

0

0

0

Other comprehensive income:
Unrealized gain on investment securities

22

87

0

0

0

-

-

-

-

-

-

-

-

Comprehensive loss

-58,744

-50,335

-44,170

-37,292

-30,522

-27,054

0

0

0

-

-

-

-

Net loss per share:
Net loss per share – basic and diluted

-0.71

-0.60

-0.60

-0.51

-0.37

-0.35

-0.38

-2.41

-2.92

-1.68

-1.67

-1.22

-2.18

Weighted average shares outstanding – basic and diluted

24,488

24,236

24,208

24,161

24,095

24,375

20,016

2,307

1,870

-

1,430

1,348

-